Skip Navigation


Rheumatology Advance Access originally published online on August 18, 2009
Rheumatology 2009 48(10):1208-1212; doi:10.1093/rheumatology/kep236
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/10/1208    most recent
kep236v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lakey, R. L.
Right arrow Articles by Cawston, T. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lakey, R. L.
Right arrow Articles by Cawston, T. E.
Related Collections
Right arrow Osteoarthritis and Cartilage
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Sulfasalazine blocks the release of proteoglycan and collagen from cytokine stimulated cartilage and down-regulates metalloproteinases

Rachel L. Lakey1 and Tim E. Cawston1

1Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.

Correspondence to: Tim E. Cawston, Musculoskeletal Research Group, Institute of Cellular Medicine, 4th Floor, Catherine Cookson Building, The Medical School, Framlington Place, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. E-mail: t.e.cawston{at}ncl.ac.uk


  Abstract

Objective. To investigate the effect of SSZ on the release of GAG and collagen fragments from bovine nasal cartilage and MMP and ADAMTS (a disintegrin and metalloproteinase domain with thrombospondin motifs) proteinases from human articular chondrocytes (HACs) stimulated with IL-1{alpha} and oncostatin M (OSM).

Methods. SSZ was added to bovine nasal explant cultures stimulated to resorb with IL-1{alpha} and OSM, and the release of GAG and collagen has been determined. Collagenolytic activity was measured using the radio-labelled collagen bioassay. HACs were treated with IL-1{alpha} and OSM with and without SSZ, and MMP-1 and -13 and ADAMTS-4 and -5 were measured for protein and gene expression by ELISA and RT–PCR, respectively.

Results. SSZ blocked GAG and collagen fragment release from bovine cartilage, and reduced active and total collagenase activity in a dose-dependent manner. SSZ transcriptionally blocked MMP-1, -13 and ADAMTS-4, and reduced the protein levels of MMP-1 and -13 in a dose-dependent manner following stimulation of HACs with IL-1{alpha} and OSM.

Conclusion. This study shows for the first time that SSZ blocks release of proteoglycan and collagen fragments from resorbing cartilage and lowers the levels of proteoglycan and collagen-degrading enzymes. These results indicate that in addition to acting as an anti-inflammatory agent, SSZ may have a therapeutic role in protecting cartilage from damage in OA.

KEY WORDS: RA, OA, IL-1{alpha}, TNF-{alpha}, MMPs, Oncostatin M, SSZ, GAG, Hydroxyproline

Submitted 28 October 2008; revised version accepted 7 July 2009.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.